Here are the DEF 14A proxy statements from Silo Pharma, Inc. (SILO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow SILO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SILO filings page.
Silo Pharma, Inc. is asking shareholders to vote at its 2026 annual meeting on August 14, 2026 at 11:00 a.m. Eastern in Sarasota, Florida. Holders of common stock as of June 18, 2026, when 1,128,610 shares were outstanding, may vote.
Shareholders will elect four directors, ratify Salberg & Company, P.A. as independent auditor for 2026, consider a common stock increase proposal, and approve a potential adjournment. The board is four members, three of whom are Nasdaq‑independent, and oversees audit, compensation, and nominating committees.
The proxy details executive compensation, including a $350,000 base salary for CEO Eric Weisblum and $60,000 for CFO Daniel Ryweck, plus stock option awards and severance terms for the CEO. It also describes the Amended and Restated 2020 Omnibus Equity Incentive Plan and current equity reserves.